Protein Inhibitors - Imatinib mesylate (CAS: 220127-57-1)

Imatinib mesylate (CAS: 220127-57-1)

Catalog #：EBC51116

Biological Activity

Synonyms

Gleevec, STI571, STI-571

Chemical Name

4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide mesylate

Application

Imatinib mesylate is a c-Abl, PDGFR, and c-kit inhibitor that halts chronic myelogenous leukemia related growth

CAS Number

220127-57-1

Purity

≥99.0%

Molecular Weight

589.73

Molecular Formula

C₃₀H₃₅N₇O₄S

SMILES

CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O

Target & IC50

PDGFR: IC50 = 0.1 μM
c-Kit: IC50 = 0.1 μM
K562 cells : IC50 = 0.21 μM
v-Abl: IC50 = 0.6 μM

Shipping

Gel Pack

Storage

Store at -20°C

Preparing Stock Solutions

Molecular Structure

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	1.6957 ml	8.4787 ml	16.9575 ml
5 mM	0.3391 ml	1.6957 ml	3.3915 ml
10 mM	0.1696 ml	0.8479 ml	1.6958 ml
50 mM	0.0339 ml	0.1696 ml	0.3392 ml

Solubility
DMSO: 59 mg/mL (100 mM) H2O: 59 mg/mL (100 mM)

Product Description

Imatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia (CML). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produces the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib mesylate binds up this crucial kinase, halting CML related growth. Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. Formulations containing Imatinib mesylate have been used in the treatment of various cancers.